IPHA Innate Pharma S.A. ADRs

Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France. This is an ADR of a company whose stock trades outside of the U.S. as the symbol FP:IPH.

$3.86  -0.09 (-2.30%)
As of 05/10/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  France
Country of incorporation:  
IPO date:  10/17/2019
Outstanding shares:  78,989,740
Average volume:  4,100
Market cap:   $312,088,463
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.93
PS ratio:   2.02
Return on equity:   -76.95%
Net income %:   -94.65%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy